India-based Sun Pharma has suspended the supply of its bicalutamide to Beijing, Tianjin, Jilin, Shanghai, Fujian, Henan, Yunnan, and Tibet due to non-compliance with importing standards caused by “loss on drying.” The national alliance procurement office has designated Hisun Pharma, Zhendong Pharma, and Zhaohui Pharma as the new suppliers for the affected regions.
Supply Changes
- Hisun Pharma: To supply Beijing, Jilin, and Shanghai.
- Zhendong Pharma: To supply Tianjin, Henan, and Tibet.
- Zhaohui Pharma: To supply Fujian and Yunnan.
Background
Sun Pharma is not the only manufacturer to lose its volume-based procurement (VBP) winning bid status. Previously, BeiGene/Celgene’s albumin paclitaxel, North China Pharma’s ibuprofen sustained-release capsules, and Salvage Pharma’s glimepiride faced similar issues. North China Pharma was barred from participating in VBP from August 11, 2021, to May 10, 2022.-Fineline Info & Tech
